Literature DB >> 16361276

Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis.

O Elkayam1, R Segal, M Lidgi, D Caspi.   

Abstract

OBJECTIVES: To determine the prevalence of anti-cyclic citrullinated proteins (anti-CCP) and IgM rheumatoid factor (RF) in sera of patients with TB compared with healthy controls. PATIENTS AND METHODS: 47 consecutive patients with recently diagnosed active pulmonary TB and 39 healthy controls were studied. Data were collected by questionnaire on clinical features of the disease, duration of symptoms, fever, cough, arthralgia, myalgia, sicca symptoms. Serum samples were collected from patients before starting treatment for TB and frozen at -20 degrees C. Anti-CCP and IgM RF were evaluated by ELISA.
RESULTS: The mean (SD) duration of TB related symptoms was 4.4 (1.7) months, 73% had fever, 94% a cough. Rheumatic symptoms were relatively rare: arthralgia (4%), myalgias (4%), eye and mouth dryness (2% and 9%, respectively). Mean (SD) levels of anti-CCP were significantly increased in patients with TB compared with controls: 44.9 (51) IU v 20 (7.3) IU (p = 0.002). Serum levels >40 U were found in 15/47 (32%) patients compared with 1/39 (2.6%) controls (p = 0.002). Mean (SD) serum levels of IgM RF were significantly increased in patients with TB: 17.8 (19) v 4.3 (5) (p<0.0001). IgM RF was positive (>6 IU) in 29/47 (62%) patients v 1/39 (2.6%) controls (p<0.0001).
CONCLUSIONS: A significant proportion of patients with active TB have an increased titre of anti-CCP and IgM RF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16361276      PMCID: PMC1798246          DOI: 10.1136/ard.2005.045229

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

1.  Comparison of rheumatoid factors of rheumatoid arthritis patients, of individuals with mycobacterial infections and of normal controls: evidence for maturation in the absence of an autoimmune response.

Authors:  N Djavad; S Bas; X Shi; J Schwager; M Jeannet; T Vischer; E Roosnek
Journal:  Eur J Immunol       Date:  1996-10       Impact factor: 5.532

2.  Autoantibodies in malaria, tuberculosis and hepatitis B in a west African population.

Authors:  A O Adebajo; P Charles; R N Maini; B L Hazleman
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

Review 3.  Tuberculosis of bones and joints.

Authors:  H G Watts; R M Lifeso
Journal:  J Bone Joint Surg Am       Date:  1996-02       Impact factor: 5.284

Review 4.  Current concepts of childhood tuberculosis.

Authors:  Anna M Mandalakas; Jeffrey R Starke
Journal:  Semin Pediatr Infect Dis       Date:  2005-04

5.  Poncet's disease in a north Indian hospital.

Authors:  R Sood; J P Wali; R Handa
Journal:  Trop Doct       Date:  1999-01       Impact factor: 0.731

6.  Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis.

Authors:  B Vander Cruyssen; I E A Hoffman; H Zmierczak; M Van den Berghe; E Kruithof; L De Rycke; H Mielants; E M Veys; D Baeten; F De Keyser
Journal:  Ann Rheum Dis       Date:  2005-02-04       Impact factor: 19.103

7.  Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia.

Authors:  Mark H Wener; Kathleen Hutchinson; Chihiro Morishima; David R Gretch
Journal:  Arthritis Rheum       Date:  2004-07

8.  Tuberculosis of the hand and wrist.

Authors:  D C Bush; L H Schneider
Journal:  J Hand Surg Am       Date:  1984-05       Impact factor: 2.230

9.  Skeletal tuberculosis mimicking seronegative spondyloarthropathy.

Authors:  Mohammed Hammoudeh; Izzat Khanjar
Journal:  Rheumatol Int       Date:  2003-05-29       Impact factor: 2.631

10.  Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.

Authors:  F A van Gaalen; S P Linn-Rasker; W J van Venrooij; B A de Jong; F C Breedveld; C L Verweij; R E M Toes; T W J Huizinga
Journal:  Arthritis Rheum       Date:  2004-03
View more
  37 in total

1.  Anti-cyclic citrullinated peptide antibodies and rheumatoid factor sera titers in leprosy patients from Mexico.

Authors:  María G Zavala-Cerna; Mary Fafutis-Morris; Cecilia Guillen-Vargas; Mario Salazar-Páramo; Diana E García-Cruz; Carlos Riebeling; Arnulfo Nava
Journal:  Rheumatol Int       Date:  2011-11-15       Impact factor: 2.631

Review 2.  From molecular mimicry to cross-reactivity or pathogen expansion? A hypothesis.

Authors:  Alexander P Rozin
Journal:  Clin Rheumatol       Date:  2006-06-29       Impact factor: 2.980

3.  Anti-cyclic citrulline peptide antibody in non-tuberculous mycobacteria sera: a negative association.

Authors:  Mi-Kyoung Lim; Tae Sun Shim; Dong-Hyuk Sheen; Dong-Jib Na; Sun Seek Min; Seung-Cheol Shim
Journal:  Clin Rheumatol       Date:  2010-01-06       Impact factor: 2.980

Review 4.  Mycobacterium tuberculosis, autoimmunity, and vitamin D.

Authors:  Yinon Shapira; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 5.  Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.

Authors:  Rohit Aggarwal; Katherine Liao; Raj Nair; Sarah Ringold; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-11-15

Review 6.  Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance.

Authors:  M Kristen Demoruelle; Kevin Deane
Journal:  Curr Rheumatol Rep       Date:  2011-10       Impact factor: 4.592

7.  Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis.

Authors:  Prasanthi Kakumanu; Eric S Sobel; Sonali Narain; Yi Li; Jun Akaogi; Yoshioki Yamasaki; Mark S Segal; Paulette C Hahn; Edward K L Chan; Westley H Reeves; Minoru Satoh
Journal:  J Rheumatol       Date:  2009-11-02       Impact factor: 4.666

8.  Anti-cyclic citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid arthritis.

Authors:  Sujit Itty; Jose S Pulido; Sophie J Bakri; Keith H Baratz; Eric L Matteson; David O Hodge
Journal:  Trans Am Ophthalmol Soc       Date:  2008

9.  Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis.

Authors:  Susan Tseng; A Hari Reddi; Paul E Di Cesare
Journal:  Biomark Insights       Date:  2009-02-17

10.  The anti-cyclic citrullinated peptide response in tuberculosis patients is not citrulline-dependent and sensitive to treatment.

Authors:  Ori Elkayam; Refael Segal; Daniele Bendayan; Robert van Uitert; Carla Onnekink; Ger Jm Pruijn
Journal:  Arthritis Res Ther       Date:  2010-01-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.